These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15731658)

  • 21. Daclizumab to prevent rejection after cardiac transplantation.
    Hershberger RE; Starling RC; Eisen HJ; Bergh CH; Kormos RL; Love RB; Van Bakel A; Gordon RD; Popat R; Cockey L; Mamelok RD
    N Engl J Med; 2005 Jun; 352(26):2705-13. PubMed ID: 15987919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New immunosuppressive agents in pediatric renal transplantation.
    Ettenger RB
    Transplant Proc; 1998 Aug; 30(5):1956-8. PubMed ID: 9723350
    [No Abstract]   [Full Text] [Related]  

  • 23. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation.
    Hirose R; Roberts JP; Quan D; Osorio RW; Freise C; Ascher NL; Stock PG
    Transplantation; 2000 Jan; 69(2):307-11. PubMed ID: 10670644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients.
    Bruce DS; Sollinger HW; Humar A; Sutherland DE; Light JA; Kaufman DB; Alloway RR; Lo A; Stratta RJ
    Transplantation; 2001 Nov; 72(10):1637-43. PubMed ID: 11726823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Staggered immunosuppression with the interleukin-2 receptor antagonist daclizumab combined with tacrolimus, prednisolone, and mycophenolate mofetil after orthotopic liver transplantation: a pilot efficacy and safety study.
    Fahlke J; Wolff S; Mantke R; Pross M; Weiss G; Buerger T; Lippert H
    Transplant Proc; 2002 Jun; 34(4):1242-4. PubMed ID: 12072328
    [No Abstract]   [Full Text] [Related]  

  • 26. Steroid-resistant acute rejection following SPK: importance of maintaining therapeutic dosing in a triple-drug regimen.
    Burke GW; Ciancio G; Figueiro J; Olson L; Gomez C; Rosen A; Suzart K; Miller J
    Transplant Proc; 2002 Aug; 34(5):1918-9. PubMed ID: 12176628
    [No Abstract]   [Full Text] [Related]  

  • 27. [Immunosuppressive therapy after human lung transplantation].
    Cao KJ; Gao CX; Qin Y; Hu DZ; Shi JX; Yang J
    Zhonghua Wai Ke Za Zhi; 2007 Jun; 45(12):818-21. PubMed ID: 17845780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.
    Ciancio G; Burke GW; Gaynor JJ; Carreno MR; Cirocco RE; Mathew JM; Mattiazzi A; Cordovilla T; Roth D; Kupin W; Rosen A; Esquenazi V; Tzakis AG; Miller J
    Transplantation; 2005 Aug; 80(4):457-65. PubMed ID: 16123718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tacrolimus, daclizumab, sirolimus, and budesonide after small bowel transplantation in order to reduce nephrotoxicity.
    Allers C; Eichhorn J; Leckel K; Brinkmann L; Schmitz-Rixen T; Hanisch E; Markus BH
    Transplant Proc; 2002 May; 34(3):942. PubMed ID: 12034251
    [No Abstract]   [Full Text] [Related]  

  • 30. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
    Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can antibody prophylaxis allow sparing of other immunosuppressives?
    Vincenti F; Grinyo J; Ramos E; Nashan B; Stuart F; Kuypers D; Brattstrom C; Cho S; Ekberg H; Johnson R
    Transplant Proc; 1999; 31(1-2):1246-8. PubMed ID: 10083557
    [No Abstract]   [Full Text] [Related]  

  • 32. Daclizumab induction as an immunosuppressive regimen for renal transplant recipients from non-heart-beating donors.
    Sánchez-Fructuoso AI; Prats D; Marques M; Ridao N; Conesa J; García Mena M; Torrente J; Barrientos A
    Transplant Proc; 2003 Aug; 35(5):1689-90. PubMed ID: 12962759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two-dose daclizumab, tacrolimus, mycophenolate mofetil, and steroid-free regimen in de novo cardiac transplant recipients: early experience.
    Mastrobuoni S; Ubilla M; Cordero A; Herreros J; Rabago G
    Transplant Proc; 2007 Sep; 39(7):2163-6. PubMed ID: 17889125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IL-2 receptor blockers in liver transplantation: initial experience with daclizumab in Chile.
    Innocenti F; Humeres R; Zamboni M; Sanhueza E; Zapata R; Hepp J; Rius M
    Transplant Proc; 2003 Nov; 35(7):2520-1. PubMed ID: 14612001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Daclizumab and ATG versus ATG in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous [correction of simultaneus] pancreas-kidney transplantation: analysis of early outcome.
    Dette K; Woeste G; Schwarz R; Wullstein C; Bechstein WO
    Transplant Proc; 2002 Aug; 34(5):1909-10. PubMed ID: 12176624
    [No Abstract]   [Full Text] [Related]  

  • 36. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.
    Stratta RJ; Alloway RR; Hodge E; Lo A;
    Clin Transplant; 2002 Feb; 16(1):60-8. PubMed ID: 11982617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Daclizumab induction therapy associated with tacrolimus-MMF has better outcome compared with tacrolimus-MMF alone in pediatric living donor liver transplantation.
    Schuller S; Wiederkehr JC; Coelho-Lemos IM; Avilla SG; Schultz C
    Transplant Proc; 2005 Mar; 37(2):1151-2. PubMed ID: 15848653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients.
    Kandus A; Grego K; Bren AF
    Ther Apher Dial; 2005 Jun; 9(3):262-4. PubMed ID: 15967003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation.
    Pescovitz MD; Bumgardner G; Gaston RS; Kirkman RL; Light S; Patel IH; Nieforth K; Vincenti F
    Clin Transplant; 2003 Dec; 17(6):511-7. PubMed ID: 14756266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-interleukin 2-receptor antibodies: a comparative study with polyclonal antibodies in kidney transplantation: preliminary results.
    Martins L; Henriques AC; Dias L; Sarmento AM; Pereira MC; Guimarães S
    Transplant Proc; 2000 Dec; 32(8):2623-5. PubMed ID: 11134730
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.